<p><strong>Dr. Berkman</strong> is the director of the&nbsp;<a href="https://www.hsph.harvard.edu/population-development/">Harvard Center for Population and Development Studies</a>&nbsp;(HCPDS) and the Thomas D. Cabot Professor of Public Policy and of Epidemiology at the&nbsp;<a href="https://www.hsph.harvard.edu/">Harvard T.H. Chan School of Public Health</a>. She is an internationally recognized social epidemiologist whose work focuses extensively on social and policy influences on health outcomes. Her research orients toward understanding inequalities in health related to socioeconomic status, working conditions, social and economic policies, and social networks and isolation. She is the principal investigator of the&nbsp;<a href="https://haalsi.org/">Health and Aging Study in Africa: A Longitudinal Study of an INDEPTH Community in South Africa</a>&nbsp;(HAALSI), a program project funded by the National Institute on Aging. HAALSI aims to study the social, economic, and policy drivers and consequences of HIV and non-communicable diseases in an aging population in Agincourt, South Africa. &nbsp;This study also has a major study on dementia as well. &nbsp;&nbsp;She is also PI of the Robert Wood Johnson Foundation Study of Workplace Redesign for Worker Well-being: Blueprint for Resilience.</p><p><strong>Dr. Mwapasa</strong> is a public health expert, research scientist and professor at Kamuzu University of Health Sciences (formerly the University of Malawi, College of Medicine (CoM)). He has previously served in many senior positions at CoM including Associate Director of the Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Director of the Research Support Centre, Head of Department of Public Health, Dean of Postgraduate Studies and Research and Chairperson of the CoM Research and Ethics Committee. Currently, he leads the delivery of courses in HIV, Research Methodology, Public Health and Implementation Science and supervises undergraduate and postgraduate students. His research focuses on the epidemiology of malaria and HIV, including testing the efficacy and effectiveness of novel diagnostic tests and interventions and evaluating public health implementation strategies for these diseases and associated co-morbidities. He has expertise in health research capacity development in resource-limited settings and currently leads research capacity development initiatives funded by the National Institutes of Health (USA) and Wellcome Trust (UK). He serves in various national and international policy-making and strategic committees such as Malawi Pharmacy and Medicine Board, Malawi National AIDS Commission HIV Research and Surveillance Technical Working Committee and the Medical Research Council-UK, Global Health Group. &nbsp;His participation in these committees facilitates the identification of research gaps and translation of research findings into public policies and strategies. He has over 15 years experience in research focused on assessing the efficacy and safety of antimalarial and antiretroviral drugs.&nbsp; He has, also, conducted community-based studies to identify strategies for promoting the utilization of health services and access and adherence to antimalarial and antiretroviral therapy. From 2012 to 2016, he led the implementation of a WHO-funded cluster-randomized trial assessing the effectiveness of integrated clinics and the use of electronic message (SMS) reminders in improving retention of HIV-positive mothers and their infants in HIV care. He also served as the PI of Pharmaceutical Industry-sponsored clinical trials which demonstrated the efficacy and efficacy of a novel antimalarial drug (arterolane maleate/Piperaquine phosphate) in treating uncomplicated malaria in adults and children. He has led a multi-centre clinical trial, funded by the EDCTP, investigating the efficacy and safety of ACTs in people treated with antiretroviral drugs.</p>